[{"indications": "Indications\u00a0suppression of inflammatory and allergic\r\ndisorders; diagnosis of Cushing\u2019s disease, congenital adrenal hyperplasia;\r\ncerebral oedema associated with malignancy; croup (section\r\n3.1); nausea and vomiting with chemotherapy (section 8.1); rheumatic disease (section 10.1.2); eye (section 11.4.1); see also notes above", "name": "DEXAMETHASONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.3 Corticosteroids", "6.3.2 Glucocorticoid therapy", "DEXAMETHASONE"], "cautions": "Cautions\u00a0\n(From Cautions and contra-indications of corticosteroids: British National Formulary)\nCautions and contra-indications of corticosteroids", "side-effects": "Side-effects\u00a0\n(From Side-effects of corticosteroids: British National Formulary)\nSide-effects of corticosteroids; also perineal irritation may follow\r\nintravenous administration of the phosphate ester", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4272.htm", "doses": ["By mouth, usual range 0.5\u201310\u00a0mg daily; child 10\u2013100\u00a0micrograms/kg daily; see also Administration\r\n(above)", "By intramuscular injection or slow intravenous injection or infusion, see under preparations", "By intramuscular injection or slow intravenous injection or infusion, 0.4\u201320\u00a0mg; child 200\u2013400\u00a0micrograms/kg daily", "Cerebral oedema, by intravenous injection 8\u201316\u00a0mg\r\ninitially, then 5\u00a0mg by intramuscular injection or intravenous injection every 6 hours as\r\nrequired for 2\u20134 days then gradually reduced and stopped over 5\u20137\r\ndays", "Adjunctive treatment of bacterial meningitis, (starting before\r\nor with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3\u00a0mg every 6 hours for 4 days; child 3 months\u201318 years see BNF for Children", "by intramuscular injection or slow intravenous injection or infusion, 0.4\u201320\u00a0mg; child 167\u2013333\u00a0micrograms/kg daily", "Cerebral oedema associated with malignancy, by intravenous\r\ninjection 8.3\u00a0mg initially, then 3.3\u00a0mg by intramuscular\r\ninjection every 6 hours as required for 2\u20134 days then gradually\r\nreduced and stopped over 5\u20137 days", "Adjunctive treatment of bacterial meningitis, (starting before\r\nor with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3\u00a0mg every 6 hours for 4 days; child 3 months\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0\n(From Pregnancy and breast-feeding: British National Formulary)\nPregnancy and breast-feeding"}, {"indications": "Indications\u00a0suppression of inflammatory and allergic\r\ndisorders; diagnosis of Cushing\u2019s disease, congenital adrenal hyperplasia;\r\ncerebral oedema associated with malignancy; croup (section\r\n3.1); nausea and vomiting with chemotherapy (section 8.1); rheumatic disease (section 10.1.2); eye (section 11.4.1); see also notes above", "name": "DEXAMETHASONE - GLUCOCORTICOID THERAPY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.3 Corticosteroids", "6.3.2 Glucocorticoid therapy", "DEXAMETHASONE"], "cautions": "Cautions\u00a0\n(From Cautions and contra-indications of corticosteroids: British National Formulary)\nCautions and contra-indications of corticosteroids", "side-effects": "Side-effects\u00a0\n(From Side-effects of corticosteroids: British National Formulary)\nSide-effects of corticosteroids; also perineal irritation may follow\r\nintravenous administration of the phosphate ester", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4272.htm", "doses": ["By mouth, usual range 0.5\u201310\u00a0mg daily; child 10\u2013100\u00a0micrograms/kg daily; see also Administration\r\n(above)", "By intramuscular injection or slow intravenous injection or infusion, see under preparations", "By intramuscular injection or slow intravenous injection or infusion, 0.4\u201320\u00a0mg; child 200\u2013400\u00a0micrograms/kg daily", "Cerebral oedema, by intravenous injection 8\u201316\u00a0mg\r\ninitially, then 5\u00a0mg by intramuscular injection or intravenous injection every 6 hours as\r\nrequired for 2\u20134 days then gradually reduced and stopped over 5\u20137\r\ndays", "Adjunctive treatment of bacterial meningitis, (starting before\r\nor with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3\u00a0mg every 6 hours for 4 days; child 3 months\u201318 years see BNF for Children", "by intramuscular injection or slow intravenous injection or infusion, 0.4\u201320\u00a0mg; child 167\u2013333\u00a0micrograms/kg daily", "Cerebral oedema associated with malignancy, by intravenous\r\ninjection 8.3\u00a0mg initially, then 3.3\u00a0mg by intramuscular\r\ninjection every 6 hours as required for 2\u20134 days then gradually\r\nreduced and stopped over 5\u20137 days", "Adjunctive treatment of bacterial meningitis, (starting before\r\nor with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3\u00a0mg every 6 hours for 4 days; child 3 months\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0\n(From Pregnancy and breast-feeding: British National Formulary)\nPregnancy and breast-feeding"}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "DEXAMETHASONE - CORTICOSTEROIDS AND OTHER ANTI-INFLAMMATORY PREPARATIONS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5426.htm", "doses": ["Apply eye drops every 30\u201360 minutes until controlled\r\nthen reduce frequency to 4\u20136 times daily"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "DEXAMETHASONE With antibacterials", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "DEXAMETHASONE", "With antibacterials"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5428.htm", "doses": ["Apply eye drops every 30\u201360 minutes until controlled\r\nthen reduce frequency to 4\u20136 times daily", "Name[Maxitrol\u00ae (Alcon) ] Eye drops, dexamethasone 0.1%, neomycin 0.35% (as sulphate), polymyxin B sulphate 6000\u00a0units/mL, net price 5\u00a0mL = \u00a31.68Excipients  include benzalkonium chloride, polysorbate 20\nEye ointment, dexamethasone 0.1%, neomycin 0.35% (as sulphate), polymyxin B sulphate 6000\u00a0units/g, net price 3.5\u00a0g = \u00a31.44Excipients  include hydroxybenzoates (parabens), wool fatDose\u00a0apply 3\u20134 times daily or at night when\r\nused with eye drops"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "DEXAMETHASONE Single use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "DEXAMETHASONE", "Single use"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/68968.htm", "doses": ["Apply eye drops every 30\u201360 minutes until controlled\r\nthen reduce frequency to 4\u20136 times daily", "Name[Minims\u00ae Dexamethasone (Bausch & Lomb) ] Eye drops, dexamethasone sodium phosphate 0.1%, net price 20 \u00d7 0.5\u00a0mL = \u00a39.76Excipients  include disodium edetate"]}, {"indications": "Indications\u00a0eczematous inflammation in otitis externa\r\n(\n(From 12.1.1 Otitis externa: British National Formulary)\n12.1.1 Otitis externa)", "name": "DEXAMETHASONE With antibacterial", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.1 Drugs acting on the ear", "12.1.1 Otitis externa", "Anti-inflammatory preparations", "Corticosteroids", "DEXAMETHASONE", "With antibacterial"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Prolonged use of topical corticosteroid ear preparations should be avoided.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local sensitivity reactions may occur.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31401.htm", "doses": ["Name[Sofradex\u00ae (Sanofi-Aventis) ] Drops (for ear or eye), dexamethasone (as sodium metasulphobenzoate) 0.05%, framycetin sulphate 0.5%, gramicidin 0.005%. Net price 10\u00a0mL =\r\n\u00a36.25Excipients  include polysorbate 80Dose\u00a0ear, apply 2\u20133 drops 3\u20134 times daily; eye, section 11.4.1"]}, {"indications": "Indications\u00a0\n(From Intravitreal corticosteroids: British National Formulary)\nIntravitreal corticosteroids\u2014specialist\r\nuse only", "name": "DEXAMETHASONE - INTRAVITREAL CORTICOSTEROIDS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "Intravitreal corticosteroids", "DEXAMETHASONE"], "cautions": "Cautions\u00a0monitor intra-ocular pressure and for\r\nsigns of ocular infection; history of ocular\r\nherpes simplex; aphakia; retinal vein occlusion with significant retinal ischaemia; concomitant administration of anticoagulant or antiplatelet drugs", "side-effects": "Side-effects\u00a0headache, raised intra-ocular pressure, vitreous\r\ndetachment, retinal detachment, blepharitis, eyelid pruritus, cataract,\r\nvisual disturbance; also reported glaucoma, ocular\r\ninfection (including endophthalmitis)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213540.htm", "doses": ["By intravitreal injection, 700\u00a0micrograms\r\ninto the affected eye", "Concurrent administration to both eyes not\r\nrecommended. For further information on administration and repeat\r\ndosing, consult product literature"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014no information available"}]